Leone, José P. http://orcid.org/0000-0002-8537-652X
Leone, Bernardo A.
Tayob, Nabihah
Hassett, Michael J.
Leone, Julieta
Freedman, Rachel A.
Tolaney, Sara M.
Winer, Eric P.
Vallejo, Carlos T.
Lin, Nancy U.
Article History
Received: 11 December 2020
Accepted: 27 January 2021
First Online: 16 February 2021
Compliance with ethical standards
:
: JPL received research funding from Kazia Therapeutics and Merck. MJH received research support from the National Institute of Health, American Cancer Society, Brown Performance Group, and IBM. RAF has institutional research funding from Puma Biotechnology. SMT receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar. SMT has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, Oncopep, Daiichi-Sankyo, G1 Therapeutics, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol-Myers Squibb, and Nanostring. EPW consultant honoraria from Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Novartis, Seattle Genetics, and Syros; scientific advisory board for Leap; and institutional research support from Genentech/Roche. NUL receives institutional research funding from Genentech, Merck, Seattle Genetics, and Pfizer and has served as an advisor/consultant to Seattle Genetics, AstraZeneca, Daiichi-Sankyo, Denali Therapeutics, and the California Institute for Regenerative Medicine. All other authors have declared no conflicts of interest.
: Given that only deidentified data were used for this study, the study was considered exempt from Dana-Farber Cancer Institute’s Office for Human Research Studies.
: Given that only deidentified data were used for this study, the study was considered exempt from Dana-Farber Cancer Institute’s Office for Human Research Studies.